Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
FDA grants regular approval to venetoclax in combination for untreated AML » 14:29
10/16/20
10/16
14:29
10/16/20
14:29
ABBV

AbbVie

$86.70 /

+1.46 (+1.71%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

On October 16, the Food…

On October 16, the Food and Drug Administration granted regular approval to venetoclax from AbbVie (ABBV) and Genentech (RHHBY) in combination with azacitidine, decitabine, or low-dose cytarabine for newly-diagnosed acute myeloid leukemia, or AML, in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. Venetoclax was initially granted accelerated approval for this indication in November 2018. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

ABBV AbbVie
$86.70 /

+1.46 (+1.71%)

ABBV AbbVie
$86.70 /

+1.46 (+1.71%)

10/16/20 JPMorgan
AbbVie price target raised to $120 from $115 at JPMorgan
09/29/20 Berenberg
AbbVie initiated with a Hold at Berenberg
09/28/20 Mizuho
Mizuho 'incrementally more bullish' on AbbVie integration of Allergan
09/02/20 Citi
AbbVie revenue potential offsets subpoena risk, says Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
RHHBY Roche
$0.00 /

+ (+0.00%)

ABBV AbbVie
$86.70 /

+1.46 (+1.71%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

ABBV AbbVie
$86.70 /

+1.46 (+1.71%)

ABBV AbbVie
$86.70 /

+1.46 (+1.71%)

Recommendations
Roche price target lowered to CHF 370 from CHF 390 at UBS » 12:39
10/16/20
10/16
12:39
10/16/20
12:39
RHHBY

Roche

$0.00 /

+ (+0.00%)

UBS analyst Michael…

UBS analyst Michael Leuchten lowered the firm's price target on Roche to CHF 370 from CHF 390 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Thursday
Conference/Events
Roche to host sales conference call » 07:55
10/15/20
10/15
07:55
10/15/20
07:55
RHHBY

Roche

$0.00 /

+ (+0.00%)

Management discusses 3Q20…

Management discusses 3Q20 sales results on a conference call to be held on October 15 at 8 am. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Earnings
Roche confirms outlook for 2020 based on assessment of COVID-19 » 06:30
10/15/20
10/15
06:30
10/15/20
06:30
RHHBY

Roche

$0.00 /

+ (+0.00%)

Based on the current…

Based on the current assessment of the COVID-19 impact, sales are expected to grow in the low- to mid-single digit range, at constant exchange rates. Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to increase its dividend in Swiss francs further.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Earnings
Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year » 06:30
10/15/20
10/15
06:30
10/15/20
06:30
RHHBY

Roche

$0.00 /

+ (+0.00%)

Following strong sales…

Following strong sales growth in the first quarter and COVID-19 related decline in the second quarter sales stabilized in the third quarter supported by continued strong sales of new medicines and COVID-19 tests, the company said in a statement. Pharmaceuticals Division sales decreased 1 to CHF 34.3 billion, while Diagnostics Division sales grew 9% to CHF 9.7 billion, with COVID-19 testing as the main contributor. Roche CEO Severin Schwan said: "Roche is at the forefront of the fight against COVID-19 with a growing portfolio of diagnostics solutions, the development of new medicines and a number of partnerships across the industry. With the recent launch of the rapid antigen test, we further strengthened our position as a leading supplier of COVID-19 tests. At the same time, we continue to deliver solutions for patients suffering from other severe diseases. I am particularly pleased about the FDA approvals in the third quarter for three new medicines: Enspryng and Evrysdi for rare diseases, and the cancer medicine Gavreto. After the pandemic-related decline in the second quarter, sales stabilised in the third quarter due to continued strong demand for our new medicines and COVID-19 tests. Based on our current assessment, we confirm the outlook for the full-year."

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Conference/Events
Roche to host sales conference call » 04:55
10/15/20
10/15
04:55
10/15/20
04:55
RHHBY

Roche

$0.00 /

+ (+0.00%)

Management discusses 3Q20…

Management discusses 3Q20 sales results on a conference call to be held on October 15 at 8 am. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Tuesday
Conference/Events
Roche to host sales conference call » 18:00
10/13/20
10/13
18:00
10/13/20
18:00
RHHBY

Roche

$0.00 /

+ (+0.00%)

Management discusses 3Q20…

Management discusses 3Q20 sales results on a conference call to be held on October 15 at 8 am. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Over a week ago
Hot Stocks
BeyondSpring announces formation of Partnership Advisory Committee » 07:15
10/12/20
10/12
07:15
10/12/20
07:15
BYSI

BeyondSpring

$15.40 /

+0.2 (+1.32%)

, FTSV

Forty Seven

$95.50 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

BeyondSpring (BYSI)…

BeyondSpring (BYSI) announced that it has formed a Partnership Advisory Committee comprised of former pharmaceutical veterans and industry leaders. The committee is tasked with supporting BeyondSpring's business development activities related to its lead asset, Plinabulin, and other pipeline assets. Mukul Agarwal, former Vice President, Corporate Development, at Forty Seven (FTSV) and Dr. Daniel Zabrowski, former Global Head of Pharma Partnering at Roche (RHHBY) and current BeyondSpring Board member, have been appointed as initial members of the committee. The Company expects to name additional members over time. Agarwal currently serves as ReCode Therapeutics' Chief Business Officer. Zabrowski currently serves as a Venture Partner at Decheng Capital.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

FTSV Forty Seven
$95.50 /

+ (+0.00%)

BYSI BeyondSpring
$15.40 /

+0.2 (+1.32%)

BYSI BeyondSpring
$15.40 /

+0.2 (+1.32%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
02/07/20 Jefferies
Jefferies starts BeyondSpring at Buy, sees potential for new standard of care
FTSV Forty Seven
$95.50 /

+ (+0.00%)

04/16/20 Cantor Fitzgerald
Gilead may be entertaining acquisition of Arcus, says Cantor Fitzgerald
03/04/20 Wells Fargo
Gilead price target raised to $87 from $81 at Wells Fargo
03/04/20 Mizuho
Forty Seven downgraded to Neutral from Buy at Mizuho
03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$15.40 /

+0.2 (+1.32%)

  • 19
    Jun
  • 12
    Dec
  • 25
    Oct
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$15.40 /

+0.2 (+1.32%)

Hot Stocks
Roche selects Veeva Systems for cloud applications » 07:11
10/12/20
10/12
07:11
10/12/20
07:11
VEEV

Veeva

$294.53 /

+3.83 (+1.32%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Veeva Systems (VEEV)…

Veeva Systems (VEEV) announced that Roche (RHHBY) has selected Veeva Development Cloud applications globally to streamline Veeva Systems The company is switching to unified applications in Vault Clinical, Vault RIM, and Vault Quality suites to increase efficiency, enhance data quality, and drive compliance throughout the product lifecycle. "Speeding drug development and product supply are strategic priorities for innovative life sciences companies like Roche," said Rik Van Mol, vice president of Veeva Development Cloud. "Veeva Development Cloud breaks down system and process silos so life sciences companies can more quickly bring innovative treatments to patients."

ShowHide Related Items >><<
VEEV Veeva
$294.53 /

+3.83 (+1.32%)

RHHBY Roche
$0.00 /

+ (+0.00%)

VEEV Veeva
$294.53 /

+3.83 (+1.32%)

08/31/20 Morgan Stanley
Veeva price target raised to $323 from $253 at Morgan Stanley
08/28/20 FBN Securities
Veeva price target raised to $310 from $300 at FBN Securities
08/28/20 JPMorgan
Veeva price target raised to $297 from $200 at JPMorgan
08/28/20 Truist
Veeva price target raised to $320 from $222 at Truist
RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VEEV Veeva
$294.53 /

+3.83 (+1.32%)

RHHBY Roche
$0.00 /

+ (+0.00%)

VEEV Veeva
$294.53 /

+3.83 (+1.32%)

RHHBY Roche
$0.00 /

+ (+0.00%)

VEEV Veeva
$294.53 /

+3.83 (+1.32%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Roche's Genentech granted orphan designation for Atezolizumab » 11:23
10/08/20
10/08
11:23
10/08/20
11:23
RHHBY

Roche

$0.00 /

+ (+0.00%)

Roche's Genentech…

Roche's Genentech was granted orphan designation from the FDA for Atezolizumab as a treatment of soft tissue sarcoma, according to a post to the agency's website. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.